Marcela V Maus

This inventor holds 27 USPTO granted patents and 29 published patent applications and 8 EPO patents, primarily in Chimeric Antigen Receptors. Top assignees: The General Hospital Corporation, University of Pennsylvania, Novartis Ag. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Marcela V Maus. Retrieved from https://idiyas.com/inventor/marcela-v-maus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 29)

% Patents Active = 96.3

EPO Patents = 8 (Patent Applications = 30)

Average Co-Inventor Count = 3.0

ph-index = 7

Forward Citations = 419(Granted Patents)

Location History:

Wynnewood, PA (US) (2009 - 2016)
Bryn Mawr, PA (US) (2016 - 2019)
New York, NY (US) (2015 - 2023)
Lexington, MA (US) (2021 - 2024)
Boston, MA (US) (2024)

Company Filing History:

12 out of 3,079

The General Hospital Corporation

patents

12 out of 2,663

University of Pennsylvania

University of Pittsburgh

patents

5. 2 out of 301

The Children's Hospital of Philadelphia

patents

6. 1 out of 11

Forevertek Biotechnology Co., Ltd

Massachusetts Institute of Technology

patents

9. 1 out of 15

Promab Biotechnologies, Inc.

patents

10. 1 out of 1,430

The Brigham and Women's Hospital, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Chimeric Antigen Receptors

T Cell Activation

Cancer Treatment

Immune Responses

Tumor Microenvironment

Cytotoxicity

Humanized Antibodies

Ex Vivo Culture

Gene Therapy

Co-Stimulatory Domain

Signal Modulation

Immunosuppressive Cells

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600760 - CHIMERIC ANTIGEN RECEPTORS TARGETING CD79B AND CD19 (2026-04-14),

2. 12595303 - ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS THAT TARGET TACI (2026-04-07),

3. 12559562 - TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR (2026-02-24),

4. 12473343 - TARGETED T CELLS WITH CYTOTOXICITY TOWARD IMMUNOSUPPRESSIVE CELLS (2025-11-18),

5. 12459975 - Modified T cells and methods of their use (2025-11-04),

6. 12409249 - Compositions and methods for immune tolerance (2025-09-09),

7. 12378297 - Chimeric antigen receptor T cells targeting the tumor microenvironment (2025-08-05),

8. 12161668 - T cells expressing a chimeric antigen receptor (2024-12-10),

9. 12049482 - Molecular switch-mediated control of engineered cells (2024-07-30),

10. 11865167 - Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor (2024-01-09),

11. 11613574 - Methods and compositions relating to ex vivo culture and modulation of T cells (2023-03-28),

12. 11578115 - Chimeric antigen receptors based on alternative signal 1 domains (2023-02-14),

13. 11559589 - Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy (2023-01-24),

14. 11352434 - Chimeric antigen receptors targeting CD37 (2022-06-07),

15. 11332513 - Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain (2022-05-17),

Title: The Innovative Journey of Marcela V Maus

Introduction: Marcela V Maus is a pioneering inventor based in Lexington, MA, known for her groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Marcela V Maus holds several patents related to novel immunotherapy treatments for cancer, including a recent patent for a personalized cancer vaccine delivery system.

Career Highlights: With a background in immunology and oncology, Marcela V Maus has had a distinguished career working at renowned research institutions and biotech companies. She has been instrumental in developing cutting-edge therapies that harness the power of the immune system to fight cancer.

Collaborations: Throughout her career, Marcela V Maus has collaborated with leading scientists, clinicians, and biotech companies to advance the field of cancer immunotherapy. Her collaborative efforts have resulted in significant advancements in the development of personalized cancer treatments.

Conclusion: Marcela V Maus continues to be a driving force in the field of biotechnology, with her innovative research paving the way for new and effective cancer therapies. Her dedication to improving patient outcomes and her passion for innovation make her a true trailblazer in the field of medical research.

Profile summary based on public USPTO records.